7th Jul 2015 05:57
LONDON (Alliance News) - Innate Pharma SA, a French biopharmaceutical company developing therapeutic antibodies for the treatment of cancer and inflammatory diseases, announced Tuesday that the co-development and commercialisation agreement with AstraZeneca PLC on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, received HSR clearance.
The company also said that on June 30, Innate Pharma received the initial payment of USD250 million from AstraZeneca.
The companies will now begin to work together to accelerate and broaden the development of IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.
Innate Pharma has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognise and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca